: Amarin is transitioning from a growth story to a cost-disciplined turnaround play after aggressive corporate restructuring .
The decision to buy or sell depends heavily on your risk tolerance and investment horizon . Wall Street analysts currently hold a consensus "Sell" to "Hold" rating on the stock , citing a forecasted downside to an average price target of $12.00 from its current price of around $13.96 . amrn stock buy or sell
: While U.S. revenues have shrunk due to generics, the company's flagship drug, Vascepa, continues to roll out in international markets . : Amarin is transitioning from a growth story